Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
chronic obstructive pulmonary disease
Pharma
EU signs off on Regeneron and Sanofi's Dupixent for COPD
European regulators signed off on Regeneron and Sanofi’s blockbuster Dupixent to treat COPD, which is the third-leading cause of death worldwide.
Kevin Dunleavy
Jul 3, 2024 10:05am
Verona earns FDA nod for potential blockbuster to treat COPD
Jun 26, 2024 6:26pm
Dupixent data enhance Sanofi, Regeneron's pursuit of COPD nod
May 20, 2024 2:24pm
Amgen, AZ see Tezspire's promise in COPD despite trial miss
May 20, 2024 10:16am
Viatris may not have infringed on Symbicort's patents
Dec 13, 2021 3:50pm
Carlyle is buying British inhaled meds CDMO Vectura for $1.4B
May 26, 2021 8:57am
